Clinical Policy: Bronchial Thermoplasty
Reference Number: PA.CP.MP.110
Last Review Date: 09/18
Effective Date: 09/18

Description
This policy describes the medical necessity requirements for bronchial thermoplasty (BT). BT is a bronchoscopic procedure that utilizes radiofrequency ablation to reduce airway smooth muscle cells. It is designed to serve as a therapeutic option to reduce severe bronchoconstriction for severe persistent asthma.

Policy/Criteria
It is the policy of PA Health & Wellness (PHW) that bronchial thermoplasty is not medically necessary for severe asthma because its long-term safety and effectiveness has not been proven.

Background
Asthma is a common inflammatory syndrome caused by chronic, intermittent obstruction of the lower respiratory tract that affects millions of individuals. This process is mediated by several inflammatory cytokines, chemokines, adhesion molecules, and signal transduction cascades.1 T helper type 2 (T_{H}2) and type 17 (T_{H}17) CD4^+, basophils, eosinophils, mast cells, and type 2 innate lymphoid cells are crucial for mediating the asthmatic response.2

BT is a bronchoscopic procedure that applies thermal energy to the airway wall and, thereby, reduces the extent of airway smooth muscle cell hypertrophy via radiofrequency ablation.3 Some studies published on BT have tested its therapeutic potential against severe asthma.4 However, the literature recently published on BT has been controversial and the studies evaluating the efficacy of BT have not provided consistent results.

A prospective non-randomized study of 16 patients with stable mild to moderate asthma found a significant reduction in airway hyperresponsiveness without a change in FEV₁.5 The Asthma Intervention Research Trial (AIR), a randomized controlled trial that enrolled 112 patients, showed an improvement in asthma symptoms from BT but no reduction in hyperresponsiveness or FEV₁.6 The Research in Severe Asthma Trial (RISA), a small randomized study that enrolled only 32 patients, assessed the safety of BT in patients receiving high doses of steroids. Despite several complications, including hospitalizations, a difference was seen in the BT group versus control.7 Some critics argue that these studies lack the statistical power and blinded placebo control to demonstrate clear conclusions on the efficacy of BT’s clinical potential.8

In 2010, Castro et al. performed a randomized, controlled trial with 288 patients that included a placebo control. This study was called the Asthma Intervention Research Trial 2 (AIR2).9 AIR2 found a statistically significant improvement in their primary outcome, which was the score from the Asthma Quality of Life Questionnaire (AQLQ).9 However, these scores fell below a clinically meaningful threshold. There was no difference in peak flow, rescue medication use, or FEV₁.9 Moreover, several investigators have criticized the AIR2 study for failing to meet
secondary outcome measures such as safety, its patient selection, and its true efficacy.\textsuperscript{8,10,11} Thus, this study also remains controversial.

Hayes conducted a review of the available literature on BT, noting that overall the body of evidence is small and of low quality. The findings were that BT may improve quality of life outcomes, however other results including emergency department visits, symptom relief, and medication use were inconsistent across studies. BT was found to not decrease hospitalization following treatment and it actually increased hospitalization during the treatment period. Treatment with BT was associated with a statistically significant increase in complications such as wheezing, chest discomfort, night awakenings, sputum discoloration, and cough. The quality and quantity of evidence was not enough to establish the long-term safety and efficacy of the procedure.\textsuperscript{12}

Lastly, a meta-analysis of the aforementioned randomized, controlled trials by Wu, et al, suggests that while BT significantly improves AQLQ scores, there were more respiratory adverse events and hospitalizations for respiratory adverse events with BT than with medications or with placebo.\textsuperscript{13}

\textit{European Respiratory Society/American Thoracic Society}

A 2014 joint statement by the European Respiratory Society and American Thoracic Society strongly recommends that BT be performed only in adults with severe asthma, in the context of a clinical trial or independent systematic registry. They conclude that the body of evidence is of very low quality, and that long-term benefits and safety are unknown.

\textit{National Institute for Health and Care Excellence (NICE)}

NICE guidance states that in patients with severe asthma, BT has shown some improvements in symptoms, quality of life, and in reductions in exacerbations and hospital admissions. However, more evidence of long-term safety is needed, and BT should only be used after establishment of special arrangements for clinical governance, including patient consent and research or audit.

\textit{Global Initiative for Asthma}

The Global Initiative for Asthma recommends BT as a potential option for highly selected adult patients who have uncontrolled asthma despite use of recommended therapeutic regimens and referral to an asthma specialty center. Evidence is limited and long-term effects compared with control patients are unknown.

\textbf{Coding Implications}

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2018, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
CLINICAL POLICY
Bronchial Thermoplasty

CPT® Codes | Description
--- | ---
31660 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe
31661 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes

ICD-10-CM Diagnosis Codes

| ICD-10-CM Code | Description |
--- | ---
J45.X | Asthma

Reviews, Revisions, and Approvals

| Event | Date | Approval Date |
--- | --- | ---
Policy developed | 04/16 | 05/16 |
References reviewed and updated. | 04/17 | 05/17 |
Background information from ETS/ATS, NICE, and GINA added. References reviewed and updated. | 03/18 | 03/18 |

References


